Ozempic vs Wegovy: Same Drug, Different Purpose

Ozempic vs Wegovy: Same Drug, Different Purpose

Ozempic and Wegovy contain the exact same active ingredient — semaglutide — made by the same manufacturer (Novo Nordisk). The difference is what they're approved for and how they're dosed. Ozempic is FDA-approved for type 2 diabetes (max dose 2.0 mg). Wegovy is FDA-approved for chronic weight management (max dose 2.4 mg).

Understanding the difference matters for insurance coverage, prescribing, and what you can expect from each.

Side-by-Side Comparison

OzempicWegovy
Active ingredientSemaglutideSemaglutide
ManufacturerNovo NordiskNovo Nordisk
FDA indicationType 2 diabetesChronic weight management
Year approved20172021
Max dose (injection)2.0 mg weekly2.4 mg weekly
Dose options0.25, 0.5, 1.0, 2.0 mg0.25, 0.5, 1.0, 1.7, 2.4 mg
Oral formulationYes (Rybelsus, for T2D)Yes (oral Wegovy, approved 2025)
CV outcomes dataNot indicated for CV riskFDA-approved for CV risk reduction (SELECT)
List price~$935/month~$1,349/month
Insurance coverageBroad (T2D)Growing (weight management)

Why the Same Drug Has Two Names

Pharmaceutical companies routinely market the same molecule under different brand names for different indications. This is a regulatory and commercial strategy, not a medical one.

Ozempic was developed first (approved 2017) for type 2 diabetes. Novo Nordisk then conducted the STEP clinical trial program to prove semaglutide's effectiveness for weight loss at a higher dose. Wegovy was approved in 2021 specifically for chronic weight management.

Separate brands allow for:

  • Different FDA approvals — each indication requires separate clinical trials and regulatory review
  • Different insurance coverage — diabetes coverage is broader than obesity coverage
  • Different dosing — Wegovy goes to 2.4 mg; Ozempic maxes at 2.0 mg
  • Targeted marketing — patients and doctors associate each brand with its purpose

Dosing Differences

The most meaningful clinical difference between Ozempic and Wegovy is the maximum dose.

Titration StepOzempicWegovy
Starting dose0.25 mg (weeks 1-4)0.25 mg (weeks 1-4)
Step 20.5 mg (weeks 5-8)0.5 mg (weeks 5-8)
Step 31.0 mg (maintenance or continue)1.0 mg (weeks 9-12)
Step 42.0 mg (optional max)1.7 mg (weeks 13-16)
Step 5—2.4 mg (maintenance)

Wegovy's higher maximum dose (2.4 mg vs 2.0 mg) explains why the STEP trials showed more weight loss than what Ozempic typically achieves at its approved doses. The additional 0.4 mg may seem small, but it represents a 20% higher dose at the top end.

Weight Loss at Different Doses

Drug & DoseTrialDurationWeight Loss
Wegovy 2.4 mgSTEP 168 weeks-14.9%
Ozempic 2.0 mgSTEP 5 (extended dose)68 weeks~-15%
Ozempic 1.0 mgSUSTAIN-130 weeks-3.7 kg
Ozempic (off-label, general)Real-world dataVaries~5-10%
Oral Wegovy 50 mgOASIS 168 weeks-15.1%

At comparable doses, Ozempic and Wegovy produce similar weight loss — because they are the same drug. The clinical trial difference comes primarily from dose (Wegovy reaches 2.4 mg) and the trial population (STEP trials enrolled for obesity; SUSTAIN for diabetes).

Insurance and Coverage Differences

This is where the brand distinction matters most practically.

OzempicWegovy
Covered for diabetesYes (broadly)Sometimes (depends on plan)
Covered for weight lossNo (off-label)Increasingly (varies by plan)
Medicare coverageYes (for diabetes)Expanding under AOM provisions
Prior authorizationOften requiredUsually required
Step therapyMay require trying metformin firstMay require documenting failed lifestyle changes

Many patients take Ozempic off-label for weight loss because their insurance covers it for diabetes but not Wegovy for weight loss. This is common but means the patient may not reach the optimal weight loss dose (2.4 mg) since Ozempic's approved max is 2.0 mg.

Oral Wegovy

In 2025, the FDA approved oral semaglutide tablets specifically for weight loss under the Wegovy brand. This is a significant milestone — it is the first oral GLP-1 drug approved for chronic weight management.

Oral Wegovy delivered -15.1% weight loss at 68 weeks in the OASIS 1 trial — comparable to injectable Wegovy. This removes the injection barrier for patients who prefer a daily pill.

Oral semaglutide was previously only available as Rybelsus (lower doses, for type 2 diabetes). Oral Wegovy uses a higher dose (50 mg daily) optimized for weight loss.

Off-Label Use Considerations

Many doctors prescribe Ozempic off-label for weight loss because:

  • Insurance coverage for diabetes drugs is broader
  • Ozempic has been available longer with a well-established safety profile
  • Wegovy has experienced supply shortages

However, off-label use means:

  • The maximum approved Ozempic dose (2.0 mg) is lower than Wegovy's (2.4 mg)
  • Insurance may not cover the off-label use if the patient doesn't have diabetes
  • Clinical trial data specifically supporting weight loss efficacy used the Wegovy dosing

If weight loss is the primary goal, discuss with your doctor whether Wegovy (or its oral formulation) is a better fit than Ozempic.

Beyond Semaglutide: The Next Generation

Semaglutide (Ozempic/Wegovy) is a single GLP-1 agonist. Newer drugs target additional receptors for greater efficacy:

Frequently Asked Questions

Are Ozempic and Wegovy the same drug?

Yes. Both contain semaglutide, made by Novo Nordisk. The difference is the FDA indication (Ozempic for type 2 diabetes, Wegovy for weight management) and maximum dose (Ozempic 2.0 mg, Wegovy 2.4 mg).

Why is Wegovy more expensive than Ozempic?

Wegovy is priced higher (~$1,349/mo vs ~$935/mo) partly because it is marketed for weight management — a newer and less broadly covered indication. Ozempic benefits from wider insurance formulary placement for diabetes.

Can I use Ozempic instead of Wegovy for weight loss?

Many doctors prescribe Ozempic off-label for weight loss. It contains the same drug but the maximum approved dose is 2.0 mg vs Wegovy's 2.4 mg. If weight loss is your primary goal, discuss with your doctor whether Wegovy is more appropriate.

Does Wegovy come as a pill?

Yes. The FDA approved oral Wegovy (semaglutide tablets, 50 mg daily) for weight management in 2025. It produced similar weight loss to the injectable form (-15.1% at 68 weeks in OASIS 1).

Which has better insurance coverage — Ozempic or Wegovy?

Ozempic generally has broader insurance coverage because diabetes coverage is more established. Wegovy coverage for weight management is growing but still varies significantly by plan. Many plans require prior authorization for both.

What is the difference between Ozempic and Rybelsus?

Both are semaglutide made by Novo Nordisk. Ozempic is a once-weekly injection (up to 2.0 mg) for type 2 diabetes. Rybelsus is a daily oral tablet (3, 7, or 14 mg) for type 2 diabetes. They are the same molecule in different formulations.

Sources

  • Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183
  • Lincoff, A.M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. DOI: 10.1056/NEJMoa2307563
  • Knop, F.K., et al. (2023). Oral Semaglutide 50 mg Taken Once Daily in Adults with Overweight or Obesity (OASIS 1). The Lancet. DOI: 10.1016/S0140-6736(23)01185-6
  • Novo Nordisk. (2025). Wegovy Pill Availability Announcement. Press release.

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Ozempic and Wegovy are prescription medications — consult your healthcare provider to determine which is appropriate for you.

This site is not affiliated with Novo Nordisk or any pharmaceutical manufacturer.